This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Camós, M. Articles by Campo, E. Search for Related Content PubMed PubMed Citation Articles by Camós, M. Articles by Campo, E.

Gene Expression Profiling of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13) and MYST3-CREBBP Rearrangement Reveals a Distinctive Signature with a Specific Pattern of HOX Gene Expression

¹ Hematopathology Unit, ² Hematology and Pathology Departments, and ³ Genomics Unit, Hospital Clínic, IDIBAPS, University of Barcelona; and ⁴ Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Requests for reprints: Jordi Esteve, Hematology Department, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. Phone: 34-93-227-54-28; Fax: 34-93-227-54 84; E-mail: jesteve{at}clinic.ub.es.

Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) is an infrequent leukemia subtype with characteristic clinicobiological features. This translocation leads to fusion of MYST3 (MOZ) and CREBBP (CBP) genes, probably resulting in a disturbed transcriptional program of a myelomonocytic precursor. Nonetheless, its gene expression profile is unknown. We have analyzed the gene expression profile of 23 AML patients, including three with molecularly confirmed MYST3-CREBBP fusion gene, using oligonucleotide U133A arrays (Affymetrix). MYST3-CREBBP cases clustered together and clearly differentiated from samples with PML-RAR, RUNX1-RUNX1T1, and CBFß-MYH11 rearrangements. The relative expression of 46 genes, selected according to their differential expression in the high-density array study, was analyzed by low-density arrays in an additional series of 40 patients, which included 7 MYST3-CREBBP AML cases. Thus, genes such as prolactin (PRL) and proto-oncogene RET were confirmed to be specifically overexpressed in MYST3-CREBBP samples whereas genes such as CCND2, STAT5A, and STAT5B were differentially underexpressed in this AML category. Interestingly, MYST3-CREBBP AML exhibited a characteristic pattern of HOX expression, with up-regulation of HOXA9, HOXA10, and cofactor MEIS1 and marked down-regulation of other homeobox genes. This profile, with overexpression of FLT3, HOXA9, MEIS1, AKR7A2, CHD3, and APBA2, partially resembles that of AML with MLL rearrangement. In summary, this study shows the distinctive gene expression profile of MYST3-CREBBP AML, with overexpression of RET and PRL and a specific pattern of HOX gene expression. (Cancer Res 2006; 66(14): 6947-54)

This article has been cited by other articles:

				U. Bacher, A. Kohlmann, and T. Haferlach Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies Brief Funct Genomic Proteomic, May 27, 2009; (2009) elp011v1. [Abstract] [Full Text] [PDF]

				B. Xu, D. Geerts, K. Qian, H. Zhang, and G. Zhu Myeloid ecotropic viral integration site 1 (MEIS) 1 involvement in embryonic implantation Hum. Reprod., June 1, 2008; 23(6): 1394 - 1406. [Abstract] [Full Text] [PDF]

				X.-L. Liu, J.-Y. Yuan, J.-W. Zhang, X.-H. Zhang, and R.-X. Wang Differential gene expression in human hematopoietic stem cells specified toward erythroid, megakaryocytic, and granulocytic lineage J. Leukoc. Biol., October 1, 2007; 82(4): 986 - 1002. [Abstract] [Full Text] [PDF]

				E. Morgado, S. Albouhair, and C. Lavau Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation Blood, May 1, 2007; 109(9): 4020 - 4022. [Abstract] [Full Text] [PDF]